The Introduction should provide the general approach to what?

• A. The general approach to evaluating the investigational product
• B. The data monitoring committee's charter
• C. The product's patent strategy
• D. The trial's business plan

Answer: (A)

The Introduction provides the general approach to evaluating the investigational product. It sets the stage with the disease context and prior data, explains why the study is being conducted, and then outlines, at a high level, how the product will be studied—the overall objectives and the broad design used to assess safety and efficacy. This framing guides the rest of the protocol and shows readers the path the trial will take to determine how the product will be evaluated. The other items belong in separate sections: the data monitoring committee’s charter covers safety oversight details, patent strategy isn’t part of the protocol, and the trial’s business plan addresses sponsor logistics and objectives outside the scientific approach.